Free tool
FAERS Monitor: Rhapsido
Last checked: Nov 19, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations
Reports naming NDA 218436 or its brand name (Rhapsido, Remibrutinib). Reports on generic versions are filed under their own applications.
Reports
1,354
Serious
267
20% of reports
Hospitalization
43
Death reported
1
Any cause; not necessarily from the drug
Most reported reactions
MedDRA preferred terms.
- urticaria186
- petechiae185
- drug ineffective148
- contusion130
- pruritus105
- headache77
- heavy menstrual bleeding59
- nausea58
- off label use57
- condition aggravated53
- chronic spontaneous urticaria44
- rash40
- fatigue39
- cough36
- product dose omission issue34
Reports by year received
View as table
| Year | Reports |
|---|---|
| 2024 | 9 |
| 2025 | 234 |
| 2026 | 1,111 |
Disproportionality screen
Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,052,805 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.
| Reaction | Reports | PRR | 95% CI lower | Chi-squared |
|---|---|---|---|---|
| chronic spontaneous urticariaSignal | 44 | 613.0 | 455.7 | 25,281 |
| petechiaeSignal | 185 | 280.2 | 244.7 | 50,307 |
| heavy menstrual bleedingSignal | 59 | 102.5 | 79.8 | 5,795 |
| contusionSignal | 130 | 21.0 | 17.8 | 2,464 |
| urticariaSignal | 186 | 17.3 | 15.1 | 2,853 |
| pruritusSignal | 105 | 4.2 | 3.5 | 262 |
| condition aggravatedSignal | 53 | 2.7 | 2.1 | 56 |
| cough | 36 | 2.0 | 1.4 | 17 |
| headache | 77 | 1.9 | 1.5 | 33 |
| product dose omission issue | 34 | 1.8 | 1.3 | 11 |
| drug ineffective | 148 | 1.7 | 1.5 | 49 |
| rash | 40 | 1.4 | 1.1 | 5 |
| nausea | 58 | 1.1 | 0.9 | 1 |
| off label use | 57 | 1.0 | 0.8 | 0 |
| fatigue | 39 | 0.8 | 0.6 | 2 |
A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.